![](/img/cover-not-exists.png)
Results of a 2-Stage, Phase 3 Pivotal Trial, EDEMA3®: A Study of Subcutaneous DX-88 (Ecallantide), a Plasma Kallikrein Inhibitor, in Patients with Hereditary Angioedema (HAE)
LEVY, R, MCNEIL, D, LI, H, HSU, F, HORN, P, ROBERTS, JVolume:
121
Language:
english
Journal:
Journal of Allergy and Clinical Immunology
DOI:
10.1016/j.jaci.2007.12.1190
Date:
February, 2008
File:
PDF, 50 KB
english, 2008